ORIC Pharmaceuticals Discontinues Development of Lead Candidate Following Clinical Trial Failures

ORIC Pharmaceuticals Discontinues Development of Lead Candidate Following Clinical Trial Failures

Comments

Post a Comment

Popular posts from this blog

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey | Prostate Cancer and Prostatic Diseases

Image
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey | Prostate Cancer and Prostatic Diseases Review Article Open access Published: 17 October 2024 Hannah D. McManus ,  Tanya Dorff , Alicia K. Morgans , Oliver Sartor , Neal Shore &  Andrew J. Armstrong   Prostate Cancer and Prostatic Diseases ( 2024 ) McManus, H.D., Dorff, T., Morgans, A.K. et al. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis (2024). https://doi.org/10.1038/s41391-024-00906-z   47 Accesses ...
Read more

The Other Patient: Care for the Caregivers

Image
Informed Prostate Cancer Support Group (IPCSG) Newsletter  |  April 2026 What Our Partners and Caregivers Carry on This Roller Coaster A close look at the hidden burden borne by spouses and care partners across surgery, ADT, radiation, imaging, and theranostics   Prepared for the IPCSG Community  |  April 2026 Bottom Line Up Front (BLUF) When a man is diagnosed with prostate cancer and embarks on treatment — whether surgery, radiation, androgen deprivation therapy (ADT), PSMA imaging, or the newest theranostics — his spouse or care partner shoulders a second, often invisible, patient journey alongside him. Research consistently shows that partners experience rates of anxiety and depression equal to or greater than patients, sacrifice thousands of hours of work and personal time, suffer significant sexual and intimacy losses, and receive far less clinical attention th...
Read more

Actinium-225 Theranostics for Advanced Prostate Cancer:

Image
 A Patient's Guide to the State of the Science An IPCSG patient-education feature — April 2026 BLUF (Bottom Line Up Front):   Actinium-225 (Ac-225) PSMA-targeted alpha therapy is producing some of the most striking PSA response numbers ever seen in heavily pretreated mCRPC — about 65% of men achieve a PSA50 response across pooled studies, a figure that exceeds what beta-emitting Lu-177 PSMA delivers in the same setting. It is showing meaningful activity even in men who have already progressed through Pluvicto (Lu-177 PSMA-617). However, Ac-225 PSMA therapy is not a finished product: it remains investigational only — no Ac-225 drug has FDA approval for prostate cancer as of April 2026 — and the dominant problem is severe, often permanent, dry mouth (xerostomia) from off-target damage to the salivary glands, which is reported in roughly 80–85% of treated patients. A wave of randomized phase 2/3 trials (PSMAcTION, CONVERGE-01, AcTION, TATCIST, ACCEL, AlphaBreak...
Read more